20/20 BIOLABS, INC.
AIDX · Consumer Discretionary · $2.8M mkt cap · FY2025 filings · No moat ·
Doesn't clear the bar
The five investor questions
2024–2025: revenue 1752343.00 to 2045133.00, increasing; diluted EPS -1.16 to -0.76, increasing. Two-year history is scoreable but carries less confidence than a full-cycle record.
Median gross margin 25.1% over 2y, variable.
Not enough years of ROIC data to score returns on capital.
Net debt/EBITDA n/ax, interest coverage -21x.
Owner earnings trend unclear, share count growing (dilution).
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
Price vs. owner-earnings value range
- Owner earnings (normalized)
- —
- Value range / share
- —
- Conservative high estimate / share
- —
- Recent price
- $0.51
- Price vs. high estimate
- No price data
Conservative range under moat-index@2.0.0: low end 11.1×, high end capped at 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
3 years of fundamentals
The business, in plain English
20/20 BIOLABS, INC. booked $2.0M of revenue in FY2025 in the Consumer Discretionary sector and kept 29.6% of it as gross profit — a moderate-margin business by that measure. After every other cost, −182.8% of each revenue dollar reached the bottom line.
AIDX's filings don't disclose total debt in a form the methodology can use, so leverage is treated as unmeasured — never assumed to be zero.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Not disclosed in AIDX’s filings for these years — we don’t estimate it.
Gaps in a line mean that item isn’t in AIDX’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Moat Score history
Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.
Consumer Discretionary context
#350 of 482 scored Consumer Discretionary companies, ranked by Moat Score.
Nearest peers by Moat Score
- #348MSS Maison Solutions Inc.35.7 out of 100, No moatNo moat
- #349NEO NEOGENOMICS, INC.35.6 out of 100, No moatNo moat
- #351CANN TREES CORPORATION35.6 out of 100, No moatNo moat
- #352QVCAQ QVC GROUP, INC.35.4 out of 100, No moatNo moat
Compare AIDX with its nearest peers →All Consumer Discretionary companies on the Index →
Common questions about AIDX
- Does 20/20 BIOLABS, INC. have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores 20/20 BIOLABS, INC. (AIDX) 35.6 out of 100 — below the Shallow-moat bar, so no moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 70, pricing power 21, returns on capital not measurable from the filings, balance-sheet safety 28, capital discipline 24.
- How has AIDX's Moat Score changed over time?
- The record logs 5 readings since Jul 18, 2026; the latest reads 35.6 out of 100 (no moat). No tier changes on record yet. (A methodology upgrade on Jul 20, 2026 re-based the score; readings across engine versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.